• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vaccine. Safety and immunogenicity of prepandemic H5N1 influenza vaccines: A systematic review of the literature.

Giuseppe

Emeritus
[Source: US National Library of Medicine, (LINK). Edited.]

Vaccine. 2010 Apr 16. [Epub ahead of print]

Safety and immunogenicity of prepandemic H5N1 influenza vaccines: A systematic review of the literature.

Prieto-Lara E, M?ndez AL. - Andalusian Agency for Health Technology Assessment, Emerging Technologies Observatory, Avd de la Innovaci?n s/n, Edificio Renta Sevilla, Planta 2, 41020 Seville, Spain.

A systematic review was performed to assess the safety and immunogenicity of the prepandemic H5N1 influenza vaccines licensed so far. A bibliographic search according to the COSI protocol was carried out and 8 of 235 potentially relevant publications were selected. Quality assessment was defined with both CASP and Jadad checklists. Taken together, the results from the present systematic review suggest that the inactivated split-virion formulation that includes a low antigen dose (3.8mug) and an oil-in-water emulsion-based adjuvant, represents the best option in the case of a pandemic, due to its antigen-sparing capacity and its favorable safety profile.

Copyright ? 2010 Elsevier Ltd. All rights reserved.

PMID: 20403350 [PubMed - as supplied by publisher]
-
-----
 
Back
Top Bottom